Start date: 16th September 2009
End date: 18th September 2009
Location: Shanghai Pudong, China
Are you facing the following challenges?
All the listed challenges are driving global pharma industry to consider more external sourcing along the entire value chain, from traditional non-core functions such as manufacturing and clinical trials to the technically demanding areas such as drug discovery and biotech R&D. Global expenditure on CRO services is estimated to reach over $36 bn by 2010, accounting for 22% of the pharma budget.
In recent years, continuing cost / capital advantages and development of talent and capabilities have put LCL markets particularly China in the spotlight. By 2015, Yangtze river delta will boast the world’s largest CRO cluster and also emerge to become the world's second largest R&D base for multinational pharmaceutical companies. China and India, followed by Korea & Taiwan, are now delivering a number of benefits for the pharmaceutical industry including a pool of educated and qualified scientists, intellectual property (IP) law reform and market growth. These trends are outweighing factors that had previously inhibited development, principally the uncertain regulatory frameworks and enforcement.
However, external sourcing is not a panacea as savings are reduced by additional costs including residual plant cost, logistics costs, QA costs, duties and taxes, product support and risks such as quality, IP, technology transfer, regulatory re-registration, EHS standards, supply assurance, foreign exchange, expropriation, catastrophe/stability, taxation/regulation, infrastructure, etc. How to adapt to the complex pharma market? How to breakthrough the financing bottleneck? How to protect your IPR in the new patent era? How to effectively manage external sourcing and globalization?
Shanghai, the next seedbed for future discoveries, welcomes you to come and feel the pulse of the world's fastest growing CRO marketplace. WPCS2009 will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general and best solutions put forward for the benefits of attendees.